Atea Pharmaceuticals
AVIR
131 hedge funds and large institutions have $278M invested in Atea Pharmaceuticals in 2022 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 58 increasing their positions, 28 reducing their positions, and 19 closing their positions.
5,216% more call options, than puts
Call options by funds: $9.84M | Put options by funds: $185K
107% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 28
32% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 19
4% more funds holding
Funds holding: 126 → 131 (+5)
0.44% more ownership
Funds ownership: 68.99% → 69.43% (+0.44%)
15% less capital invested
Capital invested by funds: $327M → $278M (-$48.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ABG
Ally Bridge Group
New York
|
+$3.05M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.59M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$1.42M |
| 4 |
Vontobel Holding
Zurich,
Switzerland
|
+$1.42M |
| 5 |
RC
RBF Capital
San Francisco,
California
|
+$1.36M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.56M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.8M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
-$3.58M |
| 4 |
KPF
K2 Principal Fund
Toronto,
Ontario, Canada
|
-$3.44M |
| 5 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$2.76M |
AVIR Hedge Fund Activity: Q4 2022 in Review
131 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Atea Pharmaceuticals (AVIR) for Q4 2022, worth a combined $278M — down 15% from $327M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new AVIR positions and 19 closed out — a net gain of 6 holders — while 58 added to existing stakes and 28 trimmed.
The largest buyer was Ally Bridge Group, adding an estimated $3.05M. The largest seller was Vanguard Group, cutting an estimated $7.56M.
- 131 institutional investors held Atea Pharmaceuticals (AVIR) as of Q4 2022, up from 126 in Q3 2022.
- Funds reported $278M of Atea Pharmaceuticals stock for Q4 2022, down 15% quarter-over-quarter.
- 25 funds opened new Atea Pharmaceuticals positions in Q4 2022 and 19 closed out, a net change of +6 holders.
- The largest Atea Pharmaceuticals buyer in Q4 2022 was Ally Bridge Group, an estimated $3.05M added.
- The largest Atea Pharmaceuticals seller in Q4 2022 was Vanguard Group, an estimated $7.56M sold.
Based on aggregated 13F filings for Q4 2022.